Third Rock Ventures

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers

Retrieved on: 
Friday, March 22, 2024
Professional Services, Business, Fintech, Training, Start-Up, Technology, Small Business, University, Artificial Intelligence, Education, Biotechnology, Finance, Health, MCAP, Beam Therapeutics, Eli Lilly, Membrane, Innovation, Growth, Insight Partners, Beam, The Ritz-Carlton Hotel Company, GOLD, Blumberg Capital, LYFT, AI, LPCE, Creativity, Senior advisor, Boston College High School, AUM, Former, Summit, Third Rock Ventures, VCG, Sirtris Pharmaceuticals

The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston.

Key Points: 
  • The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston.
  • The Summit is the largest undergraduate entrepreneurship and venture capital conference in the nation and will bring together founders of unicorn startups, CEOs of public companies, and renowned venture capital and private equity investors.
  • The event will convene over 55 speakers and 15 panels on Leadership, Investing, and Entrepreneurship with Advanced Tracks discussing topics ranging from biotech to investing in AI.
  • “For this year’s Entrepreneurship Summit, we are excited to build off of the momentum of last year’s leadership and take it to new heights.

Clasp Therapeutics Launches With $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers With Unparalleled Specificity

Retrieved on: 
Wednesday, March 20, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Trichloroethylene, Patient, Cancer, HLA, HHMI, Clasp, Neoplasm, Johns Hopkins University, Therapy, Immune system, Investment, Third Rock Ventures, Engineering, Vaccine

Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), launched today with $150 million in financing.

Key Points: 
  • Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), launched today with $150 million in financing.
  • The researchers’ structure-driven understanding of human leukocyte antigen (HLA)-antibody interactions enables the engineering of advanced TCEs that can precisely target common oncogenic mutations with exquisite specificity.
  • “Clasp’s proprietary technology enables immune targeting of intracellular oncogenic driver mutations to achieve durable tumor killing, even with low levels of surface presentation.
  • By binding both the T cell and the tumor cell with absolute specificity, this approach ensures immune activation against the tumor itself while sparing normal tissue, which lacks the tumor-specific mutated peptide.

Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Principal, RAPS, University, Science, Atlas, ARCH Venture Partners, Drug discovery, Patient, Biogen, Molecular biology, Senior advisor, Biochemistry, Therapy, DSM-IV codes, RNA interference, Atlas Venture, Multimedia, Third Rock Ventures, Takeda Oncology, Biotechnology Innovation Organization, Pharmaceutical industry

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of John Maraganore, Ph.D., to its Board of Directors.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of John Maraganore, Ph.D., to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20240319245625/en/
    “As Rapport sets out to build a leading precision neuroscience company, we are incredibly fortunate to have Dr. Maraganore join our board,” said Abraham Ceesay, Chief Executive Officer of Rapport.
  • “John is among a few visionary leaders who have guided a new modality from concept to a dynamic platform for drug discovery.
  • Dr. Maraganore served as founding CEO of Alnylam from 2002 to 2021, where he led the development of a novel class of medicines, referred to as RNAi therapeutics.

Bio-IT World: Venture, Innovation & Partnering Conference to Debut in Boston, Concurrent with 23rd Annual Bio-IT World Conference & Expo

Retrieved on: 
Tuesday, March 19, 2024
Cloud, Partner, Google Cloud, Conference, Innovation, AstraZeneca, Private equity, Goldman Sachs, ARCH Venture Partners, Dana–Farber Cancer Institute, Envelope (music), AI, Software, Bristol Myers Squibb, ARPA-H, Military strategy, Third Rock Ventures, Boston Millennia Partners, Economic development, State, Fireside chats, Pharmaceutical industry

BOSTON, March 19, 2024 /PRNewswire/ -- Cambridge Healthtech Institute announces the final agenda for the inaugural Bio-IT World: Venture, Innovation & Partnering Conference—a gathering of leading investors, executives, research institutions, biotech and informatics innovators, startups, and strategics whose creative partnerships are catalyzing today's drug discoveries.

Key Points: 
  • The April 17 Boston event, drawing heavily from leaders within the renowned Boston/Cambridge, Mass.
  • biotech community, will be part of the 23rd annual Bio-IT World Conference & Expo April 15-17, which will attract more than 3,000 life science and IT innovators.
  • Scott Penberthy, Chief Technology Officer, Google Cloud, will present on "Unveiling the Future: Strategic Investment Opportunities in Biotech & Drug Discovery."
  • To learn about the Bio-IT World Conference & Expo and to register, see bio-itworldexpo.com .

Remix Therapeutics Appoints Dominic Reynolds, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, February 1, 2024
Biomedicine, Senior, RNA, Science, History, Harvard University, University, Third Rock Ventures, Patient, Drug discovery, Entrepreneurship, Doctor of Philosophy, Disease, CSO, Takeda Oncology

WATERTOWN, Mass., Feb. 1, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced the appointment of Dominic Reynolds, Ph.D., as Chief Scientific Officer (CSO). Dr. Reynolds has been with Remix since its inception in 2019 and has been promoted from his previous role as Senior Vice President, Head of Drug Discovery, where he led the design and synthesis of compounds to reformat RNA.

Key Points: 
  • Dr. Reynolds brings over two decades of leadership experience building biotech companies, transformative platforms and drug discovery and development
    WATERTOWN, Mass., Feb. 1, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced the appointment of Dominic Reynolds, Ph.D., as Chief Scientific Officer (CSO).
  • As part of this planned leadership transition, former CSO Zaven Kaprielian, Ph.D., will join Remix's Scientific Advisory Board, where he will continue to advise on Remix's evolving science and pipeline.
  • "Dominic has been an invaluable member of the Remix team since company inception, and his deep expertise in drug discovery has advanced Remix's pipeline of RNA processing modulators forward.
  • Previous positions include drug discovery roles at Third Rock Ventures, Forma Therapeutics, a company he also joined on day one, and Millennium Pharmaceuticals.

Third Rock Ventures Expands Senior Team with Seasoned Biotech Executives

Retrieved on: 
Thursday, January 25, 2024
Professional Services, Health, Other Health, Other Science, Finance, Science, Biotechnology, Constellation, Bristol Myers Squibb, Vyasa, Philosophy, Biochemistry, Celgene, Patient, Outline of health sciences, Courtney, Therapy, Thought, Flare, Biology, Partnership, Rutgers University, Third Rock Ventures, GSK, University, Biogen, Harvard University, Tulane University, Economics, MBA, AB, Acquisition, Harvard Business School, Harvard College, IPO, Rock Ventures, Purdue University, Psychology, Ewing Marion Kauffman Foundation, Columbia University, Doctor of Philosophy, Jigar, Kearney (consulting firm), Beam Therapeutics

Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.

Key Points: 
  • Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.
  • Jigar, who joined Third Rock in 2021 as a venture partner, has made significant contributions to the firm’s discovery and company creation activities.
  • Steve Paul, M.D., who has been affiliated with Third Rock since 2010, has re-joined as a venture partner.
  • Prior to Third Rock, Courtney was an early employee and the chief business officer of Beam Therapeutics.

Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways

Retrieved on: 
Wednesday, January 24, 2024
Pharmaceutical, Health, Oncology, Other Health, Entrepreneurship, Vitiligo, Patient, Incyte, Therapy, Rheumatoid arthritis, JAK, Third Rock Ventures, Molecular biology, Pharmacology, Cancer, Medicine, Drug discovery, FGFR, Cholangiocarcinoma, Ruxolitinib, Non-small-cell lung cancer, COVID-19, Atopic dermatitis, PARP1, FDA, Polycythemia, Eli Lilly and Company, Medicinal chemistry, Drug, EVP, GPH, CNS, Pharmaceutical industry

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.
  • Synnovation was founded by a world-class medicinal chemistry team with a track record of developing best-in-class therapeutics.
  • Proceeds will fund the advancement of the company’s clinical and preclinical pipeline, including SNV1521 and SNV4818, as well as additional programs.
  • The company’s lead program, SNV1521, is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.

Sage Therapeutics Announces Changes to Board of Directors

Retrieved on: 
Monday, January 8, 2024
Research, Pharmaceutical, Consumer, Mental Health, Parenting, Clinical Trials, Science, Baby, Maternity, Women, Biotechnology, Neurology, Health, Johnson & Johnson, Chairperson, Retirement, Precigen, Therapy, Investment, Patient, Third Rock Ventures, Life

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the retirement of Kevin Starr from the company’s board of directors.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the retirement of Kevin Starr from the company’s board of directors.
  • Geno Germano has assumed the role of Chair of the Board of Directors.
  • Mr. Starr led the early efforts to launch Sage Therapeutics, served as CEO prior to the company’s initial public offering, and served as Chair of the Board since Sage went public in 2014.
  • “At the same time, I am thrilled to have Geno assume the role of Chair of the Board at a time of great momentum for Sage.